Amundi
MYGN icon

Amundi’s Myriad Genetics MYGN Stock Holding History

Amundi’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,976
Closed -$126K – 2134
2026
Q1 		$126K Buy
27,976
+12,367
+79% +$64.4K ﹤0.01% 1945
2025
Q4 		$96K Buy
15,609
+842
+6% +$6.11K ﹤0.01% 1813
2025
Q3 		$118K Sell
14,767
-98,428
-87% -$584K ﹤0.01% 1579
2025
Q2 		$637K Buy
113,195
+76,330
+207% +$451K ﹤0.01% 1315
2025
Q1 		$310K Sell
36,865
-7,113
-16% -$85.4K ﹤0.01% 1593
2024
Q4 		$650K Buy
43,978
+27,989
+175% +$516K ﹤0.01% 1506
2024
Q3 		$415K Buy
15,989
+1,892
+13% +$51.2K ﹤0.01% 1477
2024
Q2 		$352K Sell
14,097
-6,265
-31% -$137K ﹤0.01% 1426
2024
Q1 		$377K Buy
20,362
+3,934
+24% +$84.6K ﹤0.01% 1483
2023
Q4 		$297K Buy
16,428
+5,985
+57% +$104K ﹤0.01% 1538
2023
Q3 		$152K Sell
10,443
-15
-0.1% -$285 ﹤0.01% 1664
2023
Q2 		$243K Sell
10,458
-940
-8% -$20.5K ﹤0.01% 1556
2023
Q1 		$265K Buy
+11,398
New +$231K ﹤0.01% 1497
2021
Q3 		– Sell
-136,000
Closed -$4.16M – 1607
2021
Q2 		$4.16M Buy
+136,000
New +$3.93M ﹤0.01% 1042

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Amundi's MYGN Position: Q2 2026 in Review

Amundi sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 27,976 shares — an estimated $126K sold.

Amundi first reported a position in MYGN in Q2 2021 and held it in 14 quarters. The position peaked at $4.16M in Q2 2021. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Amundi reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
  • Amundi sold 27,976 Myriad Genetics shares in Q2 2026, an estimated $126K.
  • Amundi first reported a position in Myriad Genetics in Q2 2021 and held it in 14 quarters.
  • Amundi's Myriad Genetics position peaked at $4.16M in Q2 2021.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.